{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T06:22:56Z","timestamp":1649139776198},"reference-count":19,"publisher":"Japan Atherosclerosis Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb"],"published-print":{"date-parts":[[2000]]},"DOI":"10.5551\/jat1994.7.198","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T23:04:58Z","timestamp":1395356698000},"page":"198-202","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Bezafibrate Treatment on the Altered Lipoprotein Profiles in Hypertriglyceridemic Subjects"],"prefix":"10.5551","volume":"7","author":[{"given":"Mihoko","family":"Norioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Ryomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyoshi","family":"Ikebuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Harano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"(1) Castelli WP : The triglyceride issue : a view from Framingham. Am Heart J, 112 : 432-437, 1986","DOI":"10.1016\/0002-8703(86)90296-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"(2) Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mantarri M, Heinionen OP, and Fric MH : Joint effects of triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary risk in the Helsinki Heart Study : implications for treatment. Circulation, 85 : 37-45, 1992","DOI":"10.1161\/01.CIR.85.1.37"},{"key":"3","doi-asserted-by":"crossref","unstructured":"(3) Assman G and Sculte H : Relation of high-density lipoprotein cholesterol and triglyceride to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol, 70 : 733-737, 1992","DOI":"10.1016\/0002-9149(92)90550-I"},{"key":"4","doi-asserted-by":"crossref","unstructured":"(4) Laakso M, Lehto S, Penttila I, and Pyorala K : Lipid and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation, 88 : 1421-1430, 1993","DOI":"10.1161\/01.CIR.88.4.1421"},{"key":"5","doi-asserted-by":"crossref","unstructured":"(5) Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, and Wahli W : Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivaor-depen-dent rceptor ligand assay. Mol Endocrinol, 11 : 779-791, 1997","DOI":"10.1210\/mend.11.6.0007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"(6) Berndt J, Gaumert R, and Still J : Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver. Atherosclerosis, 30 : 147-152, 1978","DOI":"10.1016\/0021-9150(78)90057-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"(7) Stahlberg D : Effects of bezafibrate. A Hypolipidemic drug. Cardiovasc Drug Rev, 10 : 259-279, 1992","DOI":"10.1111\/j.1527-3466.1992.tb00250.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"(8) Heller F and Harvengt C : Effects of clofibrate, bezafibrate, fenofibrate and probucolon plasma lipolytic enzymes in normolipemic subjects. Eur J Clin Pharmacol, 25 : 57-63, 1983","DOI":"10.1007\/BF00544015"},{"key":"9","doi-asserted-by":"crossref","unstructured":"(9) Hatch FT and Lees RS : Practical methods for plasma lipoprotein analysis. Adv Lipid Res, 6 : 1-68, 1968","DOI":"10.1016\/B978-1-4831-9942-9.50008-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"(10) Richmond W : Preparation and properties of a cholesterol oxidase from Nacardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem, 19 : 1350-1356, 1973","DOI":"10.1093\/clinchem\/19.12.1350"},{"key":"11","doi-asserted-by":"crossref","unstructured":"(11) Fletcher MJ : A calorimetric method or estimating serum triglycerides. Clin Chem Acta, 22 : 393-397, 1968","DOI":"10.1016\/0009-8981(68)90041-7"},{"key":"12","unstructured":"(12) Hattori Y, Suzuki M, Harano Y, et al. : Development of approximate formula for LDL-chol, LDL-apo B and LDL-chol\/LDL-apo B as indices of hyperapobetalipo-proteinemia and small dense LDL. Atherosclerosis, 138 : 289-299, 1998"},{"key":"13","doi-asserted-by":"crossref","unstructured":"(13) Brewer HB : Comparative evaluation of fibric acid derivatives and HMG-CoA reductase inhibitors. Atherosclerosis, 97 : 511-519, 1991","DOI":"10.1016\/0021-9150(92)90159-E"},{"key":"14","doi-asserted-by":"crossref","unstructured":"(14) Lewis GF and Steiner G : Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev, 12 : 37-56, 1996","DOI":"10.1002\/(SICI)1099-0895(199603)12:1<37::AID-DMR154>3.3.CO;2-H"},{"key":"15","doi-asserted-by":"crossref","unstructured":"(15) Patsch JR, Gotto AM, Olivecrona T, and Eisenberg S : Formation of high density lipoprotein 2-like particles during lipolysis of very low density lipoproteins in vitro. Proc Natl Acad Sci USA, 75 : 4519-4523, 1978","DOI":"10.1073\/pnas.75.9.4519"},{"key":"16","doi-asserted-by":"crossref","unstructured":"(16) Schulzeek P, Bojanovski M, Jochim A, Canzler H, and Bojanovski D : Comparison between simvastatin and bezafbrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolemia. Lancet, 19 : 611-613, 1988","DOI":"10.1016\/S0140-6736(88)91414-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"(17) Gordon DA : Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipo-protein B lipoprotein assembly. Curr Opin Lipidol, 8 : 131-137, 1997","DOI":"10.1097\/00041433-199706000-00002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"(18) Blasi F, Sommariva D, Cosentini R, Cavaiani B, and Fasoli A : Bezafibrate inhibits HMG-CoA reductase activity in incubated blood mononuclear cells from normal subjects and patients with heterozygous familial hypercholesterolemia. Pharmacol Res, 21 : 247-254, 1989","DOI":"10.1016\/S1043-6618(89)80002-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"(19) Moulin P, Bourdillon MC, Parascau L, Perot L, Ponsin G, and Berthezene F : High density lipoprotein alterations induced by bezafibrate in healthy male volunteers. Atherosclerosis, 67 : 17-22, 1987","DOI":"10.1016\/0021-9150(87)90260-7"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat1994\/7\/4\/7_4_198\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T15:55:14Z","timestamp":1597593314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat1994\/7\/4\/7_4_198\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000]]}},"URL":"https:\/\/doi.org\/10.5551\/jat1994.7.198","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000]]}}}